FTORPIRIMIDINY V KhIMIOTERAPII DISSEMINIROVANNOGO KOLOREKTAL'NOGO RAKA U BOL'NYKh POZhILOGO VOZRASTA


如何引用文章

全文:

详细

Рассматриваются современные возможности химиотерапии метастатического колоректального рака с использованием фторпиримидинов - фторурацила и капецитабина (Кселоды). Обсуждаются особенности противоопухолевого лечения пожилых больных, при котором на первый план выходят проблемы безопасности. Приводятся данные об эффективности и безопасности у пациентов старших возрастных групп различных фторпиримидин-содержащих режимов химиотерапии, в т. ч. в сочетании с иринотеканом, оксалиплатином и бевацизумабом. Подчеркивается, что контролируемая и управляемая токсичность, высокая эффективность и возможность амбулаторного применения делают Кселоду идеальным препаратом для лечения пожилых больных.

全文:

受限制的访问

作者简介

N. Besova

参考

  1. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-08.
  2. Thirion P, Michiels S, Pignon J.P, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an update metaanalysis. The Meta-analysis Group in Cancer. J Clin Oncol 2004;22:3766-75.
  3. Kohne C.H, Wils J, Lorens M, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003;21:3721-28.
  4. De Gramont A, Bosset J.F, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808-15.
  5. Kohne C.H, Cunningham D, Di C.F, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13:308-17.
  6. Yuste A.L, Aparicio J, Segura A, et al. Analysis of clinical prognostic factors for survival and time to Progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. Clin Colorectal Cancer. 2003;2:231-34.
  7. Comella P, Casaretti R, Sandomenico C, et al. Capecitabine, Alone and in combination in management of patients with colorectal cancer. Drugs 2008;68(7):949-61.
  8. Koukourakis G.V, Kouloulias V, Koukourakis M.J, et al. Efficacy of the oral Fluorouracil pro-drug Capecitabine in Cancer treatment: a review. Molecules 2008;13:1897-922.
  9. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-81.
  10. PrelBudman D.R, Meropol N.J, Reigner B, et al. Preliminary studies of novel oral fluoropyrimidine carbamate: Capecitabine. J Clin Oncol 1998;16:1795-802.
  11. Osterwalder O, Rutman O. Final Clinical Study Report. Protocol NO15542B. A phase 2 study of capecitabine (Ro 09 1978) in patients who have received previous treatment with paclitaxel (Taxol™) or docetaxel (Taxotere™ ) for locally advanced and/or metastatic breast cancer. Longauer M. Brown T. Niederberger W. Neuckel W. Periodic Safety Update. Review period: November 1, 1998 - April 30, 1999. Research Report B-170974 July 12, 1999.
  12. DeVita V.T. Hellman S, Rosenberg S.A. Cancer, Principles and Practice of Oncology: Lippincott-Raven 1997;1:439-40.
  13. Anand A.J. Fluorouracil cardiotoxicity. Ann Pharmacother 1994;28:374-78.
  14. Meyer C.M, Calis K.A, Burke L.B, et al. Symptomatic cardiotoxicity associated with 5-FU. Pharmacotherapy 1997;17(4):729-36.
  15. Tuxen M.K, Hansen S.W. Neurotoxicity secondary to neoplastic drugs. Cancer Treatment Reviews 1994;20:191-214.
  16. Bygrave H.A, Geh J.I, Jani Y, et al. Neurological complications of 5-fluorouracil chemotherapy: case report and review of the literature. Clin Oncol 1998;10:334-36.
  17. Gilbert M.R. The neurotoxicity of cancer chemotherapy. The Neurologist 1998;4(2):43-53.
  18. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-106.
  19. Hoff P.M, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-92.
  20. Twelves C. Capecitabine as first-line treatment in colorectal cancer: pooled data from large phase III trials, Capecitabine Colorectal Cancer Group. Eur J Cancer 2002; 38(Suppl. 2):15-20.
  21. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Onc 2003;1(Suppl. 2):18-24.
  22. Balducci L, Exetrmann M. Management of cancer in older person: practical approach. Oncol 2000;5(3):224-37.
  23. Inoyue S.K, Peduzzi P.N, Robison J.T. et al. Importance of functional measures in predicting mortality among older hospitalized patients. JAMA 1998;279:1187-93.
  24. Reuben D.B, Rubenstein L.V, Hirsch S.H, et al. Value of functional status as predictor of mortality. Am J Med 1992;93:663-69.
  25. Siu A.L, Moshita L, Blaustein J. Comprehensive geriatric assessment in a day hospital. J Am Geriatr Soc 1994;42:1094-99.
  26. Satariano W.A, Ragland D.R. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-10.
  27. Balducci L. The geriatric patient: equal benefit from equal treatment. Cancer Control 2001;8(2s):1-25.
  28. Wildiers H, Highley M.S, et al. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 2003;42(14):1213-42.
  29. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004;15:1330-38.
  30. Chiara S, Nobile M.T, Vincenti M, et al. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 1998;42:336-40.
  31. Jacobson S.D, Cha S, Sargent D.J, et al. Tolerabiliti, dose intensity, and benefit of 5-FU-based chemotherapy for advanced colorectal cancer (CRC) in the elderly. A North Central Cancer Treatment Group (NCCTG) study. Proc Am Soc Clin Oncol 2001 ;20:A587.
  32. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colirectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leu-covorin. Ann Oncol 2002;13:566-75.
  33. Feliu J, Escudero P, Llosa F, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol 2005;23:3104-11.
  34. Vincent M, Jonker D, Kerr I, et al. Reduced dose capecitabine as first-line therapy in older and less fit patients with advanced colorectal cancer. ASCO 2005. J Clin Oncol. Abstr.
  35. http://www.rocheuse.com/products/ XELODA/PI.pdf.
  36. Petrioli R, Pascucci A, Francini E, et al. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors. Anti-Cancer Drugs 2008;19:91-96.
  37. Bollina R, Beretta G, Toniolo D, et al. Capecitabine and Irinotecan (CAPIRI): A good combination in the elderly hatients with advanced colorectal cancer as first-line chemotherapy. Preliminary results of a phase II trial. Pro Am Soc Clin Oncol 2006;24:3577.
  38. Barrueco J, Marshall J, Mitchell E. Safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in mCRC patients >65 years compared with those №65: the BICC-C study. J Clin Oncol 2007;25(18S):abstr. 4076.
  39. Folprecht G, Seymour M.T, Saltz L, et al. Irinotecan/fluorouracil combination in first-line therapy for older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials, J Clin Oncol 2008;26:1443-51.
  40. Mitry E, Phelip J.M, Bonnetain F, et al. Phase III trial chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients. FFCD 2001-02 trial. Results of a planned interim analysis. Presented at: American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium; Jan 25-27, 2008, Orlando, FL. Abstr. 3524.
  41. Sastre J, Marcuello E, Massutti B, et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 2005;23:3545-51.
  42. Souglakos J, Pallis A, Kakolyris S, et al. Combination of irinotecan plus 5-fluorouracil and leucovorin as first-line treatment for elderly patients with metastatic colorectal cancer: A phase II trial. Oncology 2005;69:384-90.
  43. Cassidy J, Tabernero J, Twelves C, et al. Capecitabine plus oxaliplatin first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084-91.
  44. Goldberg R.M, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085-91.
  45. Hockster H.S, Luo W, Popa E.C, et al. Phase II study of uracil-tegafur with leucovarin in elderly (≥ 75 years old) patients with colorectal cancer: ECOG 1299. J Clin Oncol 2007; 25:5397-402.
  46. Figer A, Perez-Staub N, Carola E, et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 2007;110:2666-71.
  47. Berretta M, Bearz A, Frustaci S, et al. FOLFOX2 regimen in the treatment of advanced colorectal cancer: comparison between elderly and young patients. Ann Oncol 2006; 17:1606-07.
  48. Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Itali Cooperative Oncology Group trial 0108. Cancer 2005;104:289-99.
  49. Kozloff M, Sugrue M, Berlin J, et al. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients with metastatic colorectal cancer (mCRC): results from the BRITE observational Cohort Study. J Clin Oncol 2008;26(Suppl.):abs 4026.
  50. Puthillath A.A, Mashtare T, Wilding G, et al. A phase II study of first-line biweekly regiment of capecitabine (CAP) and bevacizumab (BV) in elderly patients with metastatic colorectal cancer. Presented at: 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; Jan 25-27, 2008, Orlando, FL. Abstr. 511.
  51. Feliu J, Salut A, Losa F, et al. Bevacizumab plus capecitabine as first-line therapy for advanced or metastatic colorectal cancer in elderly patients. Intermediate results. oncopaz cooperative group study. Presented at: 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; Jan 25-27, 2008, Orlando, FL. Abstr. 479.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2009
##common.cookie##